IFNG and autoimmune disease: Activation of IFN-γ and NF-κB signaling by treating MSCs with IFN-γ and TNF-α, normalized weak and strong MSC lines, and overall enhanced their function in immune modulation both in vitro and in vivo, suggesting that pretreatment of MSCs might provide more consistent clinical outcomes in treating CNS injuries or autoimmune diseases.